Symptoms of Low Fish Oil (Omega-3 Fatty Acids): Causes and Treatment
Deficiency
Symptoms & causes
Omega-3 fatty acid insufficiency is widespread in Western diets and associated with increased cardiovascular and inflammatory disease risk; EPA and DHA are the biologically active marine omega-3s with the strongest evidence base, and true deficiency (especially in infants) causes neurological and visual impairment — but the supplement market significantly oversells what fish oil pills achieve in already-adequate adults.
Omega-3 fatty acids are a family of polyunsaturated fats essential for brain function, vision, and controlling inflammation. While a true, acute deficiency is rare in adults, chronic low intake of the marine omega-3s EPA and DHA is extremely common and linked to dry skin, joint stiffness, fatigue, and elevated triglycerides. The most clinically urgent consequences appear in infants and developing children, where inadequate DHA can cause irreversible visual and cognitive deficits. Treatment focuses on increasing fatty fish intake or using fish oil or algae-based supplements, but the cardiovascular benefits seen in landmark trials are tied to high-dose prescription EPA, not standard over-the-counter capsules.
This is general nutrition and wellness information, not medical advice. If you're on a weight-loss medication or managing a health condition, confirm specifics with your clinician.
Symptoms of low Omega-3 fatty acids — a family of polyunsaturated fatty acids (PUFAs) sharing a double bond at the third carbon from the methyl end. Three nutritionally important forms: ALA (alpha-linolenic acid — the only essential omega-3; found in plant sources: flaxseed, chia, walnuts), EPA (eicosapentaenoic acid — C20:5n-3; primary marine omega-3 with anti-inflammatory prostaglandin/leukotriene effects), and DHA (docosahexaenoic acid — C22:6n-3; structural component of brain gray matter and retinal photoreceptors). ALA is essential (cannot be synthesized de novo); EPA and DHA are conditionally essential — the body converts ALA → EPA → DHA but conversion is inefficient (~5–10% ALA→EPA, ~0.5–5% EPA→DHA). AI for ALA: 1.6 g/day (men), 1.1 g/day (women); no established RDA for EPA+DHA but most guidelines recommend 250–500 mg/day EPA+DHA for general adults. Fish oil supplements are the most common source of preformed EPA+DHA.
Everyday signs are on the left; the ones on the right mean it's time to check in with a clinician.
Everyday signs
Common symptoms
- Dry, scaly skin and increased skin inflammation
- Dry eyes
- Fatigue and poor concentration
- Joint stiffness and pain
- Elevated triglycerides (hypertriglyceridemia)
- Increased inflammatory markers
Don't wait
See a doctor if
- In infants: any visual concerns, developmental delays, or failure to thrive — clinical DHA status evaluation warranted, particularly if formula-fed without DHA fortification or breastfed by a severely omega-3-deficient mother.
- In adults: hypertriglyceridemia (triglycerides >200 mg/dL), cardiovascular disease risk, or autoimmune/inflammatory conditions — discuss omega-3 status and treatment with a clinician.
Who is most likely to run low
Some people are more prone to falling short than others — including many people on a weight-loss journey who are simply eating less.
- People eating fewer than 2 servings of fatty fish per week (the large majority of Americans).
- Vegans and vegetarians.
- Pregnant and breastfeeding women (DHA demand peaks).
- Infants of DHA-deficient mothers.
- People with cardiovascular disease or hypertriglyceridemia.
- People with inflammatory or autoimmune conditions.
- Individuals with high vegetable oil (omega-6) intake without corresponding omega-3 intake.
What causes low Omega-3 fatty acids — a family of polyunsaturated fatty acids (PUFAs) sharing a double bond at the third carbon from the methyl end. Three nutritionally important forms: ALA (alpha-linolenic acid — the only essential omega-3; found in plant sources: flaxseed, chia, walnuts), EPA (eicosapentaenoic acid — C20:5n-3; primary marine omega-3 with anti-inflammatory prostaglandin/leukotriene effects), and DHA (docosahexaenoic acid — C22:6n-3; structural component of brain gray matter and retinal photoreceptors). ALA is essential (cannot be synthesized de novo); EPA and DHA are conditionally essential — the body converts ALA → EPA → DHA but conversion is inefficient (~5–10% ALA→EPA, ~0.5–5% EPA→DHA). AI for ALA: 1.6 g/day (men), 1.1 g/day (women); no established RDA for EPA+DHA but most guidelines recommend 250–500 mg/day EPA+DHA for general adults. Fish oil supplements are the most common source of preformed EPA+DHA.
- Low dietary fish/seafood intake — EPA and DHA are found almost exclusively in fatty fish and some seafood; populations eating less than 2 servings/week are likely insufficient.
- Vegan or vegetarian diet — no preformed EPA/DHA in plant foods; ALA conversion is insufficient for adequate EPA/DHA status.
- Infant formula without DHA (pre-2002 US formulas often lacked DHA fortification).
- Pregnancy and lactation — DHA demand increases significantly for fetal brain and retinal development.
- High omega-6 intake (linoleic acid from vegetable oils competes with omega-3 conversion enzymes, reducing ALA→EPA→DHA conversion).
- Genetic variants in FADS1/FADS2 (fatty acid desaturase genes) reducing conversion efficiency.
How low levels are diagnosed
Omega-3 index (EPA+DHA as % of total red blood cell fatty acids) — a validated measure; optimal: >8%, high risk: <4%. Plasma or serum fatty acid panel also used. Fasting triglyceride level is a practical clinical proxy (high triglycerides are strongly associated with low EPA+DHA).
How it's corrected
Most gaps close with food first, and supplementation when a clinician recommends it.
Dietary: fatty fish 2+ servings/week (salmon, sardines, mackerel, herring are rich sources). Fish oil supplements: standard over-the-counter capsules typically contain 300–600 mg EPA+DHA per 1,000 mg capsule. Pharmaceutical-grade omega-3s (Vascepa — pure EPA; Lovaza — EPA+DHA) are prescription-only for hypertriglyceridemia at 4 g/day doses. Algae-based omega-3 (DHA dominant) — the original source of marine omega-3s; suitable for vegans. Krill oil — phospholipid-bound EPA+DHA with claimed superior bioavailability but head-to-head comparisons vs. fish oil are limited and inconsistent.
How to keep levels up
2+ servings fatty fish per week for most adults; DHA-enriched prenatal vitamins for pregnant and breastfeeding women; algae-based DHA for vegans. The American Heart Association recommends omega-3 supplementation for people with known cardiovascular disease and no adequate dietary source.
When to see a clinician
Hypertriglyceridemia (triglycerides >500 mg/dL) — prescription omega-3 therapy is FDA-approved at 4 g/day to reduce triglycerides by 20–50%; OTC fish oil is inadequate at these doses and clinical guidance is needed. Any infant with developmental concerns, visual problems, or failure to thrive. Cardiovascular risk assessment should include discussion of omega-3 status.
EPA vs. DHA vs. ALA: Why Not All Omega-3s Are Equal and Why Fish Oil Is Different From Flaxseed
The term 'omega-3' is a family name, not a single nutrient, and treating all omega-3s as interchangeable is the most common mistake in supplement marketing. The three key players—ALA, EPA, and DHA—have fundamentally different roles in the body and come from different sources.
Alpha-linolenic acid (ALA) is the only truly essential omega-3, meaning the body cannot make it from scratch. It is found in plant sources like flaxseed, chia seeds, and walnuts. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the biologically active forms, found almost exclusively in fatty fish and marine algae. While the body can convert ALA into EPA and then DHA, this pathway is a biochemical bottleneck. The conversion rate of ALA to EPA is only about 5–10%, and the subsequent conversion to DHA is even lower, often less than 5%.
This inefficiency means that loading up on flaxseed oil will not reliably raise your DHA levels. EPA and DHA are structurally and functionally distinct. EPA competes with the omega-6 fatty acid arachidonic acid for the same enzymes, producing less inflammatory signaling molecules. DHA, on the other hand, is a primary structural component of the brain's gray matter and the retina's photoreceptors, where it constitutes roughly 60% of the polyunsaturated fat. This is why fish oil, which delivers preformed EPA and DHA, has a fundamentally different clinical effect than flaxseed oil.
- ALA: The essential plant-based omega-3 found in flaxseed, chia, and walnuts.
- EPA: A marine omega-3 that directly reduces inflammation by competing with omega-6 fats.
- DHA: A structural fat critical for brain and retinal function, not easily made from ALA.
Bottom line
ALA from plant sources is essential but cannot reliably provide EPA and DHA because conversion is highly inefficient — fatty fish or marine algae are the only reliable sources of the biologically active omega-3s.
The Cardiovascular Evidence: What REDUCE-IT Proved and What Meta-Analyses Showed Was More Complicated
No area of omega-3 research is more contested than heart health, and the dose and formulation matter enormously. The cardiovascular benefit of fish oil is not a single story but a tale of two very different products: prescription-strength EPA and over-the-counter fish oil.
The landmark REDUCE-IT trial, published in 2018, found that 4 grams per day of pure EPA (icosapentaenoic acid, sold as Vascepa) reduced the risk of major cardiovascular events by 25% in high-risk patients with elevated triglycerides who were already on statins. This was a definitive result for a specific, high-dose, pure-EPA formulation. However, the STRENGTH trial in 2020 tested a different high-dose formulation—a mix of EPA and DHA—against a corn oil placebo and found no cardiovascular benefit. The contrasting results have led to intense debate about whether pure EPA is superior to an EPA/DHA mix for heart outcomes.
When you step down to standard over-the-counter fish oil capsules, the evidence thins out considerably. Large Cochrane reviews and meta-analyses of trials using 1–3 grams of fish oil per day have generally found modest or null effects on cardiovascular mortality and heart attacks. The honest conclusion is that a standard fish oil pill from the supermarket is not a proven heart-saving intervention. The strong cardiovascular data belongs to a high-dose prescription drug, not a dietary supplement.
- REDUCE-IT (2018): Pure EPA at 4 g/day reduced cardiovascular events by 25% in high-risk patients.
- STRENGTH (2020): An EPA+DHA mix at 4 g/day showed no cardiovascular benefit.
- OTC Fish Oil Meta-analyses: Standard doses (1-3 g/day) show weak or no effect on heart attack and stroke risk.
Bottom line
Prescription-dose pure EPA (4 g/day Vascepa) has landmark cardiovascular evidence in statin-treated patients with elevated triglycerides — OTC fish oil at standard doses does not have the same quality of evidence and should not be presented as equivalent.
DHA and Brain/Retinal Development: The Most Clinically Urgent Omega-3 Deficiency
While adult omega-3 insufficiency is a long-term risk factor, DHA deficiency in early life is a medical emergency with irreversible consequences. DHA is not just another fat; it is the most abundant polyunsaturated fatty acid in the brain's gray matter and the light-sensing photoreceptors of the retina.
The fetal brain undergoes a rapid growth spurt in the third trimester and the first two years of life, accumulating DHA at a massive rate. If the maternal diet or infant formula lacks sufficient DHA, this structural development is compromised. Clinical studies have shown that infants fed DHA-deficient formula had significantly lower visual acuity compared to breastfed infants or those receiving DHA-fortified formula. This is not a subtle statistical difference; it is a measurable deficit in a child's ability to see.
This evidence was strong enough that the FDA authorized a health claim for DHA in infant formula, and most prenatal vitamins now include 200–300 mg of DHA. For anyone who is pregnant or considering pregnancy, ensuring DHA adequacy is one of the most evidence-based nutritional interventions available. It is not a marketing claim; it is a developmental necessity.
- DHA makes up roughly 60% of the polyunsaturated fats in the retina's photoreceptors.
- The fetal brain accumulates DHA rapidly in the third trimester and first 2 years of life.
- DHA-deficient infant formula has been directly linked to reduced visual acuity in clinical trials.
Bottom line
DHA deficiency during fetal and infant development causes irreversible visual and cognitive impairment — this is the most clinically urgent omega-3 deficiency and the strongest evidence-based reason to ensure DHA adequacy in pregnancy.
Anti-Inflammatory Effects and Autoimmune Conditions: Real Mechanisms, Modest Clinical Gains
The anti-inflammatory reputation of fish oil is biochemically sound but clinically modest. EPA works by competing with arachidonic acid, an omega-6 fat, for the COX and LOX enzymes that produce inflammatory molecules. By partially replacing arachidonic acid, EPA shifts production toward less potent prostaglandins and leukotrienes. EPA and DHA are also precursors to specialized pro-resolving mediators (SPMs) like resolvins and protectins, which actively help shut down inflammation.
This elegant mechanism has been tested in human trials for conditions like rheumatoid arthritis, with mixed but generally positive results. Meta-analyses show that high doses of 3–4 grams of EPA and DHA per day can modestly reduce joint pain and morning stiffness, and some patients are able to slightly reduce their use of non-steroidal anti-inflammatory drugs (NSAIDs). However, the benefit is a reduction in symptoms, not a halt to disease progression. Omega-3s cannot replace disease-modifying antirheumatic drugs (DMARDs).
The evidence for other inflammatory conditions like psoriasis and inflammatory bowel disease is even less consistent. The key takeaway is that the anti-inflammatory doses used successfully in trials are far higher than what most people get from a single daily fish oil capsule. A real anti-inflammatory effect requires a deliberate, high-dose strategy, not a casual supplement habit.
- EPA competes with omega-6 fats to produce less inflammatory signaling molecules.
- Specialized pro-resolving mediators (SPMs) from EPA and DHA actively resolve inflammation.
- Clinical benefits for rheumatoid arthritis are seen at high doses (3-4 g/day) but are symptom-modifying, not disease-modifying.
Bottom line
Omega-3s have genuine anti-inflammatory mechanisms but clinical benefits in autoimmune conditions are modest — relevant at higher doses (3–4 g/day) than most people take, and not a substitute for disease-modifying drugs.
Fish Oil and GLP-1 Therapy: Triglycerides, Drug Interactions, and the Anticoagulant Warning
For patients on GLP-1 medications like semaglutide or tirzepatide, fish oil is a complementary, not competitive, therapy for cardiometabolic health. GLP-1 drugs reduce triglycerides by 20–30% in clinical trials, and omega-3s lower triglycerides through a different mechanism in the liver. The two can work together to improve a key cardiovascular risk marker.
The critical safety issue is the anticoagulant effect of fish oil. At high doses of 3 grams or more of EPA and DHA per day, fish oil inhibits platelet aggregation and can prolong bleeding time. This is a real, clinically significant interaction for patients on warfarin, clopidogrel, or even high-dose aspirin—a population that overlaps significantly with the cardiovascular-risk GLP-1 patient group. Anyone on a prescription blood thinner must discuss fish oil supplementation with their prescriber.
A less obvious but practical concern is dietary displacement. GLP-1-driven appetite suppression can lead to smaller portions of all foods, including fatty fish. For a patient whose baseline diet already lacked adequate seafood, this can unintentionally worsen an omega-3 insufficiency. Assessing omega-3 intake is a worthwhile part of a comprehensive care plan for patients using GLP-1 therapy for weight loss or diabetes.
- GLP-1 drugs and omega-3s lower triglycerides through different, complementary mechanisms.
- High-dose fish oil inhibits platelet aggregation, creating a real bleeding risk with anticoagulants.
- Appetite suppression from GLP-1s can reduce dietary fatty fish intake, potentially worsening insufficiency.
Bottom line
GLP-1 therapy and omega-3s are complementary for cardiovascular risk and triglycerides — but high-dose fish oil (≥3 g/day) carries a real anticoagulant interaction risk in the cardiovascular-risk GLP-1 population that prescribers should address.
What most pages leave out
Competitor content presents fish oil as a broad anti-inflammatory, brain-protective, heart-saving supplement at standard OTC doses. The honest distinctions: (1) The cardiovascular evidence is strongest for prescription-dose pure EPA (Vascepa 4 g/day) in high-risk populations — OTC fish oil at 1 g/day does not carry the same evidence; (2) The anti-inflammatory clinical benefits in autoimmune disease are modest and dose-dependent; (3) The anticoagulant interaction at high doses is consistently underreported; (4) Algae-based DHA is biologically equivalent to fish oil DHA and better for vegans and the environment, but is rarely mentioned as an alternative.
We flag this so you can make an informed choice — not to scare you off.
❓Frequently Asked Questions
In adults, chronically low omega-3 intake can cause dry, scaly skin, dry eyes, fatigue, poor concentration, joint stiffness, and elevated triglycerides. The most clinically severe manifestation occurs in infants and developing children, where DHA deficiency can lead to visual impairment and cognitive deficits.
For healthy adults, most guidelines recommend 250–500 mg of combined EPA and DHA per day. For cardiovascular risk reduction, doses of 1,000–4,000 mg may be used depending on the specific indication, but high doses of 3 grams or more per day require clinician guidance due to potential anticoagulant effects.
The evidence is mixed and highly dose-dependent. High-dose prescription EPA (Vascepa, 4 g/day) reduced cardiovascular events by 25% in the landmark REDUCE-IT trial in high-risk patients. However, standard over-the-counter fish oil at lower doses has shown much weaker or null effects on cardiovascular outcomes in large meta-analyses.
Not reliably from plant foods alone. The body's conversion of ALA from sources like flaxseed and walnuts into the active EPA and DHA is highly inefficient. Vegans and vegetarians should consider an algae-based DHA and EPA supplement to ensure adequate intake of these critical fatty acids.
Yes, high-dose fish oil (3 grams or more of EPA and DHA per day) inhibits platelet aggregation and can increase bleeding time. This is clinically relevant for people on anticoagulants like warfarin or clopidogrel, and fish oil is often recommended to be stopped one to two weeks before surgery. Discuss your use with a prescriber.
Krill oil's EPA and DHA are bound to phospholipids, which some claim offers superior bioavailability compared to the triglyceride form in fish oil. However, head-to-head trials are inconsistent, and krill oil typically provides far less EPA and DHA per capsule at a significantly higher cost.
DHA is critical for fetal brain and retinal development. A daily intake of 200–300 mg of DHA during pregnancy and lactation is recommended in most guidelines, and many prenatal vitamins now include DHA. Ensuring adequate DHA status is a genuine priority for fetal health.
There is no direct pharmacokinetic interaction between semaglutide and fish oil. Both can lower triglycerides through different, complementary mechanisms. The main concern in a GLP-1 patient population is the anticoagulant effect of high-dose fish oil, particularly for those also taking prescription blood thinners.
Medically reviewed by
Chet Tharpe, MDBoard-certified physician
Last reviewed July 2026
Related Articles
Symptoms of Low Black Currant Seed Oil: Causes and Treatment
Black currant seed oil is not an essential nutrient, and no recognized deficiency exists. Learn why GLA is synthesized by the body and what the oil is actually used for.
Read moreHow Fish Oil / Omega-3 Fatty Acids Interacts With Weight Loss Medications
Fish oil has no direct drug interaction with semaglutide or tirzepatide, but GI upset and high-dose antiplatelet effects matter. A practical, honest guide.
Read moreSymptoms of Low Krill Oil: Causes, Treatment, and the Evidence
Krill oil is not a nutrient — no deficiency syndrome exists. It is an EPA/DHA source in phospholipid form with astaxanthin. Learn the evidence, cost, and GLP-1 context.
Read moreSymptoms of Low Borage Oil: Causes and Treatment
Borage oil is not an essential nutrient and no deficiency syndrome exists. Learn about its GLA content, eczema and RA evidence, and the critical pyrrolizidine alkaloid safety concern.
Read moreSymptoms of Low Branched-Chain Amino Acids (BCAAs): Causes and Treatment
BCAAs are essential amino acids you must get from food. Learn the real symptoms of low BCAA intake, why protein matters more than supplements, and what to do.
Read moreSymptoms of Low CBD Oil (Cannabidiol): Causes & Treatment
CBD is not a nutrient and no deficiency syndrome exists. Learn the truth about 'endocannabinoid deficiency,' CBD's real drug interaction risks, and what the evidence actually shows.
Read moreOn a GLP-1, or thinking about one?
Nutrient gaps are more common on a GLP-1 because you eat less — care that includes real clinical oversight helps you do it safely.Curex connects you with licensed clinicians for compounded GLP-1 medications, if it's right for you.
- Compounded semaglutide from $49/mo, tirzepatide from $149/mo
- Prescribed by licensed clinicians after an online visit
- Delivered to your door — no in-person clinic required
This content is for general informational purposes only and is not medical or nutritional advice, a diagnosis, or a substitute for professional judgment. It does not account for your health, medications, or goals, and nutrition information changes over time. Always talk with a qualified clinician or dietitian before making significant changes to your diet, supplements, or medications. Curex offers compounded GLP-1 medications through licensed clinicians and does not sell or endorse the food or supplement reviewed on this page.